Pre-IPO Beijing Mabworks Biotech - MIL62 Alone Cannot Save the Situation
This article mainly analyzed Mabworks Biotech in terms of the important clinical-stage drug candidates (MIL62, MIL93, MBS301, MIL97, MIL95, MIL86,...
426 Views
Shanghai Junshi Bioscience - Here Are the Challenges
The article analyzed the concerns and challenges that Junshi has to face in terms of PD-1, COVID-19 antibody drug, other products in the pipeline...
383 Views
Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma
This article mainly analyzed Innovent in terms of its current listed products (Sintilimab, Bevacizumab, Adalimumab and Rituximab), its pipeline,...
542 Views
Insights on China Healthcare Policy: New Intensive Procurement Policy for High-Value Medical Devices
The article analyzed potential impact of China's new intensive procurement policy on high-value medical devices. If interested in investing China...
357 Views
Shanghai/Shenzhen Connect - $8.5 Bn of Inflow in January (Kweichow Moutai, Gree, Midea)
In our Discover SZ/SH Connect series, we aim to help our investors understand the flow of northbound trades via the Shanghai Connect and Shenzhen...
576 Views